Atlantic International Corp. (ATLN) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Diagnostics & Research secteur d'activité. Le siège social de l'entreprise est situé à Billerica, MA, United States. Le PDG actuel est Jeffrey Jagid.
ATLN a date d'introduction en bourse 2021-08-27, 300 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $167.3M.
As of June 18, 2024, Atlantic International Corp. was acquired by Lyneer Investments, LLC, in a reverse merger transaction. Atlantic International Corp. operates as a life sciences instrumentation and research services company. It focuses on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provides solutions for various applications, such as biomarker discovery and diagnostic assay developments, including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and Weizmann Institute of Science for developed and applied innovative single-molecule technologies. The company was formerly known as SeqLL Inc. and changed its name to Atlantic International Corp. in June 2024. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.
